Biovie Inc Asset Resilience Ratio
Biovie Inc asset resilience ratio. Biovie Inc (BIVI) has an Asset Resilience Ratio of 0.00% as of June 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Biovie Inc (BIVI) liquidity interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Biovie Inc (2016–2024)
Asset resilience ratio of Biovie Inc from 2016 to 2024. This chart shows how Biovie Inc's Asset Resilience Ratio has changed over time. Read BIVI liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Biovie Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see BIVI asset base.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Biovie Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Biovie Inc Industry Peers by Asset Resilience Ratio
Compare Biovie Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Biovie Inc Asset Resilience Ratio by Year (2016–2024)
Biovie Inc asset resilience ratio by year from 2016 to 2024. The table below shows the annual Asset Resilience Ratio data for Biovie Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-06-30 | 0.00% | $0.00 | $25.21 Million | -- |
| 2023-06-30 | 41.24% | $14.48 Million | $35.10 Million | -- |
| 2022-06-30 | 0.00% | $0.00 | $20.11 Million | -- |
| 2019-06-30 | 0.00% | $0.00 | $2.57 Million | -- |
| 2018-06-30 | 0.00% | $0.00 | $2.18 Million | -- |
| 2017-06-30 | 0.00% | $0.00 | $2.36 Million | -- |
| 2016-06-30 | 0.00% | $0.00 | $2.72 Million | -- |
About Biovie Inc
BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 3 for the treatment of life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism. It also develops Be… Read more